LOGIN  |  REGISTER
Assertio
Assertio

Travere Therapeutics to Present at Upcoming Investor Conferences

November 04, 2024 | Last Trade: US$17.18 0.22 -1.26

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in November:

Guggenheim Securities Healthcare Innovation Conference
Monday, November 11, 2024, at 2:30 p.m. ET

Jefferies London Healthcare Conference
Wednesday, November 20, 2024, at 8:30 a.m. GMT

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com. 

Contact: 
Investors:
888-969-7879                                        
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
888-969-7879                                        
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB